To become part of the standard of care in doctors’ offices and hospitals and to be covered by health insurance, new medications and procedures go through a rigorous testing process.
Physician-scientists from the Department of Radiation Oncology at Cedars-Sinai Cancer will present the latest research breakthroughs and discuss advances in clinical care at the American Society for Radiation Oncology (ASTRO) annual meeting Oct. 1-4, 2023, in San Diego.
RUDN University chemists and colleagues from China built several machine learning models and discovered a group of potential drugs that inhibit the enzyme responsible for uncontrolled cell division.
A new drug encourages weight loss and increases endurance by making the body act like it is exercising.
When children undergo cancer treatment, they may be offered the chance to participate in a clinical trial. Clinical trials can provide access to new, groundbreaking therapies in a safe and controlled environment.
The Trauma and Transfusion Medicine Research Center (TTMRC) in the Department of Surgery at the University of Pittsburgh School of Medicine is launching a $34 million, federally funded clinical trial to simultaneously test multiple interventions for life-threatening bleeding in at least 1,000 traumatically injured children across 20 U.S. pediatric trauma centers.
Researchers will need fewer mice to study lung infections thanks to improvements in dosing methods, according to a new study from the University of California San Francisco (UCSF).
Women aged 18 to 44 living in states that outlaw Sunday liquor sales or driving with a blood alcohol concentration greater than .08 drink less than their counterparts in other states, according to a new study recently published in Alcohol: Clinical and Experimental Research.
The study led by King’s College London, compared the safety and efficacy of ciclosporin with methotrexate in children and young people with this debilitating skin condition. They also examined whether the severity of the disease changed or returned after treatment ended.
The use of cell therapy to treat COVID-19 patients can reduce the risk of death from the disease by 60%, according to a systematic review and meta-analysis conducted by researchers at the University of São Paulo (USP) in Brazil, in partnership with colleagues in Germany and the United States.
UCI researchers have found that a simple sugar, N-acetylglucosamine, reduces multiple inflammation and neurodegeneration markers in people who suffer from multiple sclerosis (MS). In addition, they also found this dietary supplement improved neurological function in 30% of patients.
A five-year, $3.3 million grant to develop a molecular diagnostic test for congenital syphilis has been awarded to researchers from UTHealth Houston by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, part of the National Institutes of Health.
Phase I clinical trials provide an opportunity for cancer patients to access novel drugs or combinations of drugs for those in need of new options. Experts from Hackensack Meridian Hackensack University Medical Center’s John Theurer Cancer Center have now established a satellite phase I clinical trial program at Hackensack Meridian Jersey Shore University Medical Center.
The American Society for Radiation Oncology (ASTRO) announced today the 10 studies to be highlighted in the 2023 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held October 2 and 3 at the San Diego Convention Center and via live webcast.
A phase 2 study, led by Thomas W. Ferkol, MD, at the UNC School of Medicine, demonstrates safety and efficacy of idrevloride with hypertonic saline for treatment of primary ciliary dyskinesia, a rare genetic disorder that can lead to permanent lung damage.
As part of its partnership with the Patient-Centered Outcomes Research Institute (PCORI), Medical Care has published its first PCORI-sponsored article collection, which provides specific information about the costs that healthcare systems can expect to incur in promoting the uptake of specific evidence-based programs.
Researchers from UChicago will lead the next phase of the Illinois Precision Medicine Consortium (IPMC)'s participation in the National Institutes of Health's All of Us Research Program.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.Reporting on wildfire smoke? Fred Hutch clinicians and researchers are available to their expertise.
A new Columbia Nursing study analyzes the performance of ADscreen, a computerized speech processing algorithm that is being developed to support clinicians in detecting and monitoring the progression of Alzheimer's disease and related dementias early.
Wits Bone Research Lab the only unit of its kind to show that a bone-forming protein can block growth of human squamous cell
The Ohio State University Wexner Medical Center on Wednesday randomized the first patient in the world in a clinical trial evaluating the effectiveness of a device designed to alleviate heart failure symptoms.
A new opinion piece published in Health Affairs Forefront raises questions around current approaches to assess drug safety and effectiveness in people with obesity.
The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine.
In June 2021, Bob McCarrick and his wife Stacey headed out to Los Angeles to enroll in the MIRAGE trial and start radiation therapy.
Results from a large-scale clinical trial could increase usage of high resolution imaging for guiding interventional coronary procedures
This method produced enrollment rates many times higher than is typically seen for patient portal based recruitment – and unexpectedly increased racial and ethnic participation as well. So it could be a promising new tool to improve research recruitment and diversity in biomedical research.
The U.S. Food and Drug Administration is approving more novel pharmaceutical drugs based on single clinical trials and with less public disclosure about those trials than was the norm just a few years ago, a pair of recent studies from Oregon State University found.
Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
The Speech Accessibility Project is almost halfway through its first phase of gathering voice recordings from people with Parkinson’s. Project participant and Parkinson's advocate Ethan Henderson can comment.
$9 million grant awarded to researchers with UC San Diego School of Medicine supports new study of semaglutide for liver disease.
Researchers at RUSH are seeking volunteers to explore how a change in diet may improve brain health after a stroke. The study, called NOURISH — short for Nutrition Effects on Brain Outcomes and Recovery in Stroke After Hospitalization — aims to prevent cognitive and memory decline that is common in stroke survivors.
Cultivated autologous limbal epithelial cells (CALEC) transplant, in which stem cells from the healthy eye and transplanted into the injured eye, for significant cornea injuries was found safe and led to gains in preliminary phase I clinical trial.
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
For the first time, researchers have found a potential drug candidate that improved outcomes for patients with a type of childhood brain tumor for which there are no effective treatments. The compound, called ONC201, nearly doubled survival for patients with diffuse midline glioma (DMG) or diffuse intrinsic pontine glioma (DIPG), compared to previous patients.
The Food and Drug Administration announced yesterday the approval of HEPZATO Kit to treat ocular melanoma that has spread to the liver. HEPZATO uses a hepatic delivery system to inject the chemotherapy drug melphalan into the liver, a procedure referred to as percutaneous hepatic perfusion (PHP). Moffitt Cancer Center’s Jonathan S. Zager, M.D., was the lead international principal investigator on the multinational FOCUS phase 3 clinical trial to test the procedure, which is manufactured by Delcath Systems, Inc.
A clinical trial evaluating the role of statins in the risk of recurrent intracerebral hemorrhage (ICH) in patients presenting with ICH, has opened for enrollment at UTHealth Houston.
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI).
Following up on positive results from preliminary research, scientists at University of Utah Health are evaluating whether an eight-week program based on positive psychology techniques can improve the mood and well-being of people who have had a stroke and those who care for them.
The New Mexico Cancer Care Alliance (NMCCA) has rebranded as the New Mexico Cancer Research Alliance (NMCRA) to strengthen its focus on delivering cancer clinical trials to New Mexicans. Through the NMCRA’s unique collaboration, every New Mexican has access to cancer clinical trials. Cancer clinical trials test new treatments and new methods of delivering and improving cancer care.
20221027104337.jpg&width=400&height=400)
One common side effect of treatment for ovarian cancer is chemotherapy-induced peripheral neuropathy (CIPN), which can damage peripheral nerves, causing severe pain and numbness. The effects can last for months – or even years — after completing chemotherapy. Currently, there is only one treatment with limited efficacy for CIPN.
Sanoj Punnen, M.D., co-chair of the Genitourinary Site Disease Group at Sylvester Comprehensive Cancer Center and associate professor and vice chair of research, Desai Sethi Urology Institute, at the University of Miami Miller School of Medicine, is leading a $2.5 million, five-year National Cancer Institute (NCI) grant to explore a new way to noninvasively detect prostate cancer.
A machine commonly used for pain relief has shown to improve breathing in patients with obstructive sleep apnoea, a clinical trial has found.
Since its inception in 2014, Insilico Medicine has developed multiple AI models for predicting the probability of success of clinical trials focusing on Phase II to Phase III transition probabilities.
Helen is an 8 1/2-year old gentle giant who’s fighting osteosarcoma and, through participation in a clinical trial through the Animal Cancer Care and Research Center, is helping develop a new cancer treatment. The dog's owners have a 1-year-old son enrolled in a clinical trial for a rare liver disease, which gave them the idea to also enroll Helen in a clinical trial.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
